wtkr.com |
Full Results Released for Failed EXPEDITION3 Trial of Solanezumab for Mild AD Dementia
Medscape Full results of the failed phase 3 EXPEDITION3 trial of solanezumab (Eli Lilly) for patients with mild dementia from Alzheimer's disease (AD) were presented last night to a packed room at the Clinical Trials on AD (CTAD) meeting in San Diego, California. Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's … Despite failed trials, experts believe we'll have an Alzheimer's drug by 2025 Lilly Continues Alzheimer's Efforts |
